Novartis (NYSE:NVS) - Stock Price, News & Analysis

NVS Stock Overview

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.

About the company

NVS fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	5/6
Financial Health	4/6
Dividends	5/6

Rewards

Trading at 55.1% below our estimate of its fair value

Earnings are forecast to grow 10% per year

Earnings grew by 52.4% over the past year

Pays a reliable dividend of 3.66%

Risk Analysis

Large one-off items impacting financial results

Novartis AG Competitors

Johnson & Johnson

NYSE:JNJ

US$353.8b

Pfizer

NYSE:PFE

US$143.0b

Bristol-Myers Squibb

NYSE:BMY

US$99.3b

Zoetis

NYSE:ZTS

US$70.1b

Price History & Performance

Summary of all time highs, changes and price drops for Novartis
Historical stock prices
Current Share Price	CHF99.06
52 Week High	CHF108.78
52 Week Low	CHF92.19
Beta	0.47
1 Month Change	3.98%
3 Month Change	-7.56%
1 Year Change	-3.50%
3 Year Change	15.15%
5 Year Change	20.91%
Change since IPO	1,043.55%

Novartis Looks To Get Back On Track With Q1 Earnings

Apr 19

Recent updates

Shareholder Returns

	NVS	US Pharmaceuticals	US Market
7D	7.0%	-0.6%	1.0%
1Y	-3.5%	10.6%	21.9%

Return vs Industry: NVS underperformed the US Pharmaceuticals industry which returned 10.6% over the past year.

Return vs Market: NVS underperformed the US Market which returned 21.9% over the past year.

Price Volatility

Is NVS's price volatile compared to industry and market?
NVS volatility
NVS Average Weekly Movement	2.6%
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.0%

Stable Share Price: NVS has not had significant price volatility in the past 3 months.

Volatility Over Time: NVS's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1996	76,057	Vas Narasimhan	www.novartis.com

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

Novartis AG Fundamentals Summary

How do Novartis's earnings and revenue compare to its market cap?
NVS fundamental statistics
Market cap	US$201.29b
Earnings (TTM)	US$9.11b
Revenue (TTM)	US$47.73b

22.1x

P/E Ratio

4.2x

P/S Ratio

Is NVS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NVS income statement (TTM)
Revenue	US$47.73b
Cost of Revenue	US$12.12b
Gross Profit	US$35.61b
Other Expenses	US$26.51b
Earnings	US$9.11b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Jul 18, 2024

Earnings per share (EPS)	4.46
Gross Margin	74.61%
Net Profit Margin	19.08%
Debt/Equity Ratio	64.2%

How did NVS perform over the long term?

See historical performance and comparison

Dividends

3.7%

Current Dividend Yield

89%

Payout Ratio

NVS Stock Overview

Rewards

Risk Analysis

Novartis AG Competitors

NYSE:JNJ

US$353.8b

NYSE:PFE

US$143.0b

NYSE:BMY

US$99.3b

NYSE:ZTS

US$70.1b

Price History & Performance

Recent News & Updates

Novartis and Medicines for Malaria Venture Announce Positive Efficacy and Safety Data for A Novel Treatment for Babies

Novartis AG Revise Earnings Guidance for the Year 2024

Novartis Looks To Get Back On Track With Q1 Earnings

Novartis' Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market

Novartis Presents Results from Pre-Specified Interim Analysis of the Phase III APPLAUSE-IgAN study of Fabhalta

Novartis Fabhalta Receives Positive CHMP Opinion as First Oral Monotherapy for Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Recent updates

Novartis and Medicines for Malaria Venture Announce Positive Efficacy and Safety Data for A Novel Treatment for Babies

Novartis AG Revise Earnings Guidance for the Year 2024

Novartis Looks To Get Back On Track With Q1 Earnings

Novartis' Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market

Novartis Presents Results from Pre-Specified Interim Analysis of the Phase III APPLAUSE-IgAN study of Fabhalta

Novartis Fabhalta Receives Positive CHMP Opinion as First Oral Monotherapy for Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Novartis AG (SWX:NOVN) acquired IFM Due, Inc. from IFM Therapeutics, LLC for approximately $840 million.

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Novartis AG Announces FDA Approves Xolair® (Omalizumab) as First and Only Medicine for Children and Adults with One or More Food Allergies

Novartis Reportedly in Lead to Acquire MorphoSys

Novartis AG Provides Earnings Guidance for the Year 2024

Novartis AG to Report Q1, 2024 Results on Apr 23, 2024

Novartis AG Presents Data from the Phase III NETTER-2 Trial

Novartis Pursuit of Cytokinetics Reportedly Cools

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

Novartis AG Announces Positive Results from the Primary Analysis of ASC4FIRST

Novartis AG (SWX:NOVN) acquired SanReno Therapeutics from Pivotal bioVenture Partners China, Versant Venture Management, LLC, Samsara BioCapital LLC, Frazier Healthcare Partners managed by Frazier Management, L.L.C. and Frazier Life Sciences Management, LP.

Novartis Investigational Iptacopan Phase III Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients with C3 Glomerulopathy (C3G)

Latest Novartis Kisqali(R) Natalee Analysis Reinforces 25% Reduction in Risk of Recurrence Across Broad Population of Patients with Early Breast Cancer

Novartis Receives FDA Approval for Fabhalta (iptacopan) Offering Superior Hemoglobin Improvement in the Absence of Transfusions as the First Oral Monotherapy for Adults with PNH

Novartis AG to Report Q4, 2023 Results on Jan 31, 2024

Novartis Announces New Positive Data from the Phase III REMIX-1 and REMIX-2 Studies Investigating Remibrutinib

Novartis Announces US Food and Drug Administration Approves Cosentyx® to Treat Moderate to Severe Hidradenitis Suppurativa in Adults

Novartis Announces Positive Topline Results from the Interim Analysis of the Ongoing Pivotal Phase III ALIGN Study

New And Improved Novartis

Novartis AG Announces Impairment Charges for the Third Quarter of 2023

Novartis AG Raises Earnings Guidance for the Fiscal Year 2023

Novartis Kisqali Natalee Analysis Confirms Consistent Reduction in Risk of Recurrence Across Key Sub Groups of Patients with Early Breast Cancer

FDA Approves Novartis Cosentyx® as First Intravenous (Iv) Formulation Interleukin-17A Antagonist for Rheumatic Diseases

Novartis to Present New Oncology Data at ESMO 2023 Demonstrating Practice-Changing Innovation in Advanced Prostate and Early Breast Cancer

Novartis: Better Margin Visibility Ex-Sandoz

Novartis AG completed the Spin-Off of Sandoz Group AG (SWX:SDZ).

Bausch & Lomb Ireland completed the acquisition of ophthalmology assets of Novartis AG from Novartis AG for $2.5 billion.

Sandoz, Novartis Division, Receives European Commission Approval for Tyruko (Natalizumab), First and Only Biosimilar for Multiple Sclerosis in Europe

Novartis: Buy This Dividend Aristocrat For Consistent Income

Novartis Radioligand Therapy Lutathera® Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival in First Line Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Novartis AG Issues Voluntary Nationwide Recall of One Lot of Sandimmune Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization

Novartis AG Announces Executive Changes

Novartis Presents New Long-Term Leqvio (Inclisiran) Data Demonstrating Consistent Efficacy and Safety Beyond Six Years

Sandoz Announces Positive Results from Mylight Phase III Study for Biosimilar Aflibercept

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Novartis Ag Announces Positive Top-Line Results from the Phase Iii Remix-1 and Remix-2 Studies Evaluating Remibrutinib 25 Mg B.I.D

Novartis: Strong Growth And Continued Expansion For KISQALI

Novartis AG (SWX:NOVN) acquired DTx Pharma, Inc. for $1 billion.

US FDA Approves Expanded Indication for Novartis Leqvio® (Inclisiran) to Include Treatment of Adults with High LDL-C and Who Are at Increased Risk of Heart Disease

Bausch + Lomb Corporation (NYSE:BLCO) signed an agreement to acquire ophthalmology assets from Novartis AG (SWX:NOVN) for $2.5 billion.

Shareholder Returns

Price Volatility

About the Company

Novartis AG Fundamentals Summary

22.1x

4.2x

Earnings & Revenue

Dividends

3.7%

89%